Detalles de la búsqueda
1.
Talazoparib plus enzalutamide in men with first-line metastatic castration-resistant prostate cancer (TALAPRO-2): a randomised, placebo-controlled, phase 3 trial.
Lancet
; 402(10398): 291-303, 2023 07 22.
Artículo
en Inglés
| MEDLINE | ID: mdl-37285865
2.
Sex and survival outcomes in patients with renal cell carcinoma receiving first-line immune-based combinations.
Cancer Immunol Immunother
; 73(8): 142, 2024 Jun 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-38832989
3.
Global real-world experiences with pembrolizumab in advanced urothelial carcinoma after platinum-based chemotherapy: the ARON-2 study.
Cancer Immunol Immunother
; 73(6): 106, 2024 Apr 18.
Artículo
en Inglés
| MEDLINE | ID: mdl-38634928
4.
Use of concomitant proton pump inhibitors, statins or metformin in patients treated with pembrolizumab for metastatic urothelial carcinoma: data from the ARON-2 retrospective study.
Cancer Immunol Immunother
; 72(11): 3665-3682, 2023 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-37676282
5.
Efficacy of Grignard Pure to Inactivate Airborne Phage MS2, a Common SARS-CoV-2 Surrogate.
Environ Sci Technol
; 57(10): 4231-4240, 2023 03 14.
Artículo
en Inglés
| MEDLINE | ID: mdl-36853925
6.
Plain language summary of the design of the TALAPRO-2 study comparing talazoparib and enzalutamide versus enzalutamide and placebo in men with metastatic castration-resistant prostate cancer.
Future Oncol
; 18(27): 2979-2986, 2022 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-35950899
7.
Talazoparib plus enzalutamide in metastatic castration-resistant prostate cancer: TALAPRO-2 phase III study design.
Future Oncol
; 18(4): 425-436, 2022 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-35080190
8.
Mechanisms of acquired resistance to rapalogs in metastatic renal cell carcinoma.
PLoS Genet
; 14(9): e1007679, 2018 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-30256787
9.
Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial.
Lancet Oncol
; 21(12): 1574-1588, 2020 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-32971005
10.
The LACOG-0415 phase II trial: abiraterone acetate and ADT versus apalutamide versus abiraterone acetate and apalutamide in patients with advanced prostate cancer with non-castration testosterone levels.
BMC Cancer
; 19(1): 487, 2019 May 23.
Artículo
en Inglés
| MEDLINE | ID: mdl-31122212
11.
Molecular Subtypes Improve Prognostic Value of International Metastatic Renal Cell Carcinoma Database Consortium Prognostic Model.
Oncologist
; 22(3): 286-292, 2017 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-28220024
12.
Risk factors and model for predicting toxicity-related treatment discontinuation in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy: Results from the International Metastatic Renal Cell Carcinoma Database Consortium.
Cancer
; 122(3): 411-9, 2016 Feb 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-26540173
13.
Association of tumour microRNA profiling with outcomes in patients with advanced urothelial carcinoma receiving first-line platinum-based chemotherapy.
Br J Cancer
; 115(1): 12-9, 2016 06 28.
Artículo
en Inglés
| MEDLINE | ID: mdl-27351382
14.
Whole-Exome Sequencing in Two Extreme Phenotypes of Response to VEGF-Targeted Therapies in Patients With Metastatic Clear Cell Renal Cell Carcinoma.
J Natl Compr Canc Netw
; 14(7): 820-4, 2016 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-27407122
15.
10% Tumor diameter shrinkage on the first follow-up computed tomography predicts clinical outcome in patients with advanced renal cell carcinoma treated with angiogenesis inhibitors: a follow-up validation study.
Oncologist
; 19(5): 507-14, 2014 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-24755461
16.
Comparative effectiveness of approved first-line anti-angiogenic and molecularly targeted therapeutic agents in the treatment of good and intermediate risk metastatic clear cell renal cell carcinoma.
BMC Cancer
; 14: 592, 2014 Aug 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-25127891
17.
Systemic Immune-Inflammation Index in Patients Treated With First-Line Immune Combinations for Metastatic Renal Cell Carcinoma: Insights From the ARON-1 Study.
Clin Genitourin Cancer
; 22(2): 305-314.e3, 2024 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-38087702
18.
Circulating tumor cells as a predictor and prognostic tool for metastatic clear cell renal carcinoma: An immunocytochemistry and genomic analysis.
Pathol Res Pract
; 253: 154918, 2024 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-37995423
19.
Expert Consensus Recommendations on the Management of Treatment-emergent Adverse Events Among Men with Prostate Cancer Taking Poly-ADP Ribose Polymerase Inhibitor + Novel Hormonal Therapy Combination Therapy.
Eur Urol Oncol
; 2024 Jun 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-38866640
20.
First-line talazoparib with enzalutamide in HRR-deficient metastatic castration-resistant prostate cancer: the phase 3 TALAPRO-2 trial.
Nat Med
; 30(1): 257-264, 2024 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-38049622